Investors sold shares of Gilead Sciences Inc. (NASDAQ:GILD) on strength during trading hours on Thursday. $117.62 million flowed into the stock on the tick-up and $147.72 million flowed out of the stock on the tick-down, for a money net flow of $30.10 million out of the stock. Of all equities tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $0.67 for the day and closed at $79.57

A number of analysts have recently commented on GILD shares. Morgan Stanley restated a “hold” rating and set a $103.00 target price on shares of Gilead Sciences in a report on Wednesday, June 15th. Jefferies Group reiterated a “hold” rating and issued a $97.00 price target on shares of Gilead Sciences in a research note on Friday, July 15th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a research note on Sunday, July 10th. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $105.06 price target on the stock in a research note on Monday, May 2nd. Finally, Leerink Swann reiterated a “buy” rating and issued a $120.00 price target on shares of Gilead Sciences in a research note on Tuesday, June 21st. Ten research analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $107.37.

The company’s 50 day moving average is $83.04 and its 200-day moving average is $87.62. The company has a market cap of $105.12 billion and a price-to-earnings ratio of 6.99.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.02 by $0.06. During the same quarter in the previous year, the firm earned $3.15 earnings per share. The company had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.80 billion. The company’s revenue for the quarter was down 5.7% compared to the same quarter last year. Equities analysts anticipate that Gilead Sciences Inc. will post $11.77 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Friday, September 16th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.36%.

In other Gilead Sciences news, CEO John F. Milligan sold 112,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $86.94, for a total transaction of $9,737,280.00. Following the transaction, the chief executive officer now directly owns 1,170,963 shares of the company’s stock, valued at $101,803,523.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $87.02, for a total transaction of $174,040.00. Following the transaction, the executive vice president now directly owns 63,122 shares in the company, valued at $5,492,876.44. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have bought and sold shares of the company. Adirondack Trust Co. increased its position in Gilead Sciences by 6.2% in the fourth quarter. Adirondack Trust Co. now owns 12,500 shares of the biopharmaceutical company’s stock valued at $1,037,000 after buying an additional 729 shares during the period. Sfmg LLC increased its position in shares of Gilead Sciences by 5.2% in the fourth quarter. Sfmg LLC now owns 10,619 shares of the biopharmaceutical company’s stock valued at $1,075,000 after buying an additional 522 shares during the last quarter. Baxter Bros Inc. increased its position in shares of Gilead Sciences by 42.1% in the fourth quarter. Baxter Bros Inc. now owns 11,798 shares of the biopharmaceutical company’s stock valued at $1,194,000 after buying an additional 3,493 shares during the last quarter. West Chester Capital Advisors Inc. increased its position in shares of Gilead Sciences by 2.9% in the fourth quarter. West Chester Capital Advisors Inc. now owns 11,912 shares of the biopharmaceutical company’s stock valued at $1,197,000 after buying an additional 339 shares during the last quarter. Finally, P.A.W. Capital Corp increased its position in shares of Gilead Sciences by 9.1% in the fourth quarter. P.A.W. Capital Corp now owns 12,000 shares of the biopharmaceutical company’s stock valued at $1,214,000 after buying an additional 1,000 shares during the last quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.